Given that NOS2 inhibitors regress aortic disease in MFS mice19, our data suggest that the overproduction of NO by NOS2 underlies MFS aortopahy through sGC–PRKG pathway activation. This evidence concerns the gene NOS2 and Marfan syndrome.